Oak Associates LTD Gilead Sciences, Inc. Transaction History

Oak Associates LTD

$1.48 Billion
Q3 2024

A detailed history of Oak Associates LTD transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Oak Associates LTD holds 83,105 shares of GILD stock, worth $7.46 Million. This represents 0.47% of its overall portfolio holdings.

Number of Shares

83,105

Previous 82,681 0.51%

Holding current value

$7.46 Million

Previous $5.67 Million 22.8%

% of portfolio

0.47%

Previous 0.38%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$66.59 - $83.99 $28,234 - $35,611	424 Added 0.51%	83,105 $6.97 Million
Q2 2024 Aug 08, 2024	SELL	$63.15 - $72.88 $56,961 - $65,737	-902 Reduced 1.08%	82,681 $5.67 Million
Q1 2024 May 10, 2024	SELL	$71.58 - $87.29 $49,533 - $60,404	-692 Reduced 0.82%	83,583 $6.12 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $36,854 - $41,794	-503 Reduced 0.59%	84,275 $6.83 Million
Q3 2023 Nov 13, 2023	SELL	$73.94 - $80.67 $153,721 - $167,712	-2,079 Reduced 2.39%	84,778 $6.35 Million
Q2 2023 Aug 11, 2023	SELL	$76.01 - $86.7 $2.42 Million - $2.76 Million	-31,868 Reduced 26.84%	86,857 $6.69 Million
Q1 2023 May 11, 2023	SELL	$77.31 - $88.08 $812,450 - $925,632	-10,509 Reduced 8.13%	118,725 $9.85 Million
Q4 2022 Feb 09, 2023	BUY	$62.32 - $89.47 $170,819 - $245,237	2,741 Added 2.17%	129,234 $11.1 Million
Q3 2022 Nov 09, 2022	BUY	$59.54 - $68.01 $442,739 - $505,722	7,436 Added 6.25%	126,493 $7.8 Million
Q2 2022 Aug 12, 2022	SELL	$57.72 - $65.01 $92,871 - $104,601	-1,609 Reduced 1.33%	119,057 $7.36 Million
Q1 2022 May 12, 2022	SELL	$57.92 - $72.58 $672,567 - $842,798	-11,612 Reduced 8.78%	120,666 $7.17 Million
Q4 2021 Feb 10, 2022	SELL	$64.88 - $73.64 $245,051 - $278,138	-3,777 Reduced 2.78%	132,278 $9.61 Million
Q3 2021 Nov 12, 2021	BUY	$67.69 - $73.03 $473 - $511	7 Added 0.01%	136,055 $9.5 Million
Q2 2021 Aug 09, 2021	SELL	$63.47 - $69.35 $138,428 - $151,252	-2,181 Reduced 1.58%	136,048 $9.37 Million
Q1 2021 May 13, 2021	BUY	$60.0 - $68.46 $1.22 Million - $1.39 Million	20,289 Added 17.2%	138,229 $8.93 Million
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $10.2 Million - $11.6 Million	-180,120 Reduced 60.43%	117,940 $6.87 Million
Q3 2020 Nov 13, 2020	SELL	$62.1 - $78.08 $2.08 Million - $2.61 Million	-33,479 Reduced 10.1%	298,060 $18.8 Million
Q2 2020 Aug 11, 2020	SELL	$72.34 - $84.0 $297,606 - $345,576	-4,114 Reduced 1.23%	331,539 $25.5 Million
Q1 2020 May 15, 2020	BUY	$62.63 - $80.22 $123,756 - $158,514	1,976 Added 0.59%	335,653 $25.1 Million
Q4 2019 Feb 13, 2020	SELL	$61.62 - $67.78 $683,119 - $751,409	-11,086 Reduced 3.22%	333,677 $21.7 Million
Q3 2019 Nov 12, 2019	BUY	$62.51 - $69.0 $333,740 - $368,391	5,339 Added 1.57%	344,763 $21.9 Million
Q2 2019 Aug 09, 2019	BUY	$61.87 - $69.38 $32,358 - $36,285	523 Added 0.15%	339,424 $22.9 Million
Q1 2019 May 09, 2019	BUY	$62.53 - $70.05 $2.69 Million - $3.01 Million	43,032 Added 14.54%	338,901 $22 Million
Q4 2018 Feb 07, 2019	BUY	$60.54 - $79.0 $3.72 Million - $4.85 Million	61,375 Added 26.17%	295,869 $18.5 Million
Q3 2018 Nov 13, 2018	BUY	$71.28 - $78.92 $1.86 Million - $2.06 Million	26,103 Added 12.53%	234,494 $18.1 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $550,896 - $642,598	8,491 Added 4.25%	208,391 $14.8 Million
Q1 2018 May 14, 2018	BUY	$72.84 - $88.8 $14.2 Million - $17.4 Million	195,600 Added 4548.84%	199,900 $15.1 Million
Q4 2017 Feb 08, 2018	BUY	$71.15 - $83.52 $122,022 - $143,236	1,715 Added 66.34%	4,300 $308,000
Q3 2017 Nov 07, 2017	BUY	$72.11 - $85.47 $186,404 - $220,939	2,585	2,585 $209,000

Others Institutions Holding GILD

# of Institutions

1,924

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oak Associates LTD , based on Form 13F filings with the SEC.

News

Stay updated on Oak Associates LTD with notifications on news.

Account

Oak Associates LTD Gilead Sciences, Inc. Transaction History